Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.45 |
| ▸ | CCR5 | P51681 | 4/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18446124 | 0.85 | KDM4E (0.44) | CCR5TSHR | |
| SCHEMBL27313194 | 0.81 | OPRD1 (0.47) | STSALOX15TSHRATMGPR119 | |
| SCHEMBL18418237 | 0.81 | MGLL (0.49) | — | |
| SCHEMBL18422151 | 0.81 | MGLL (0.49) | — | |
| SCHEMBL16565507 | 0.81 | RORC (0.47) | RORCSTSLIMK2TGFBR1ALOX15 | |
| SCHEMBL5520738 | 0.80 | JAK2 (0.50) | STSALOX15TSHRATMGPR119 | |
| SCHEMBL18422276 | 0.79 | TGFBR1 (0.52) | RORCSTSLIMK2TGFBR1ALOX15 | |
| SCHEMBL16101520 | 0.78 | OPRD1 (0.48) | STSALOX15TSHRATMGPR119 | |
| SCHEMBL15740589 | 0.76 | USP2 (0.46) | GPR119 | |
| SCHEMBL2951728 | 0.76 | OPRD1 (0.53) | STSALOX15TSHRATMGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328849-B9 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3328849-B9 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3328849-B1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3328849-B1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10723711-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10723711-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10428034-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20180065943-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20180065943-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20180065943-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-9845301-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845301-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845301-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2017-12-19 | — | — | US | disclosed |
| WO-2017021805-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20170029390-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170029390-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170029390-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029390-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | MAG, PYM1, HIF1AN | RORC 3202/4885CCR5 1899/4885STS 4342/4885 |
| US-20180065943-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | MAG, PYM1, HIF1AN | RORC 3202/4885CCR5 1899/4885STS 4342/4885 |
| US-10723711-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | MAG, PYM1, HIF1AN | RORC 3202/4885CCR5 1899/4885STS 4342/4885 |
| US-10428034-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | MAG, PYM1, HIF1AN | RORC 3202/4885CCR5 1899/4885STS 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.